FluoGuide A/S (FLUO) AI Stock Analysis

• Market Cap: kr588.58M
• Dividend Yield: N/A
• Average Volume (3M): 8.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 4.46%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -1.28
• Shares Outstanding: 16,349,314
• 10 Day Avg. Volume: 11,579
• 30 Day Avg. Volume: 8,206
• PEG Ratio: -0.29
• Price to Book (P/B): 6.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.08
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: kr38.00 ▲(5.56% Upside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is primarily held back by weak financial performance (near-zero revenue, sustained losses, and heavy cash burn alongside increased debt). Technicals are a partial offset due to a strong uptrend, but overbought signals reduce confidence. Valuation remains unattractive because losses make P/E less meaningful and there is no dividend support.

Positive Factors

Unit Economics (Gross Profit)

Positive gross profit in revenue years indicates the core imaging agent can generate margin at the unit level. For a consumable, stable positive gross margins are a durable foundation: if volumes scale via approvals/partners, gross profit can cover fixed R&D and commercial costs, supporting a pathway to sustainable profitability.

Negative Factors

Persistent Cash Burn

Sustained large negative operating cash flows materially increase dependence on external financing. Over time this raises dilution and limits strategic optionality; it constrains the firm's ability to scale commercialization investments and could force compromises on pricing, trials, or market entry timing if new funding is delayed.

FluoGuide A/S Business Overview & Revenue Model

Company Description

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for...

Read more

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for...

How the Company Makes Money

FluoGuide’s expected revenue model is based on commercializing its fluorescent imaging agent(s) for use alongside existing fluorescence-capable surgical imaging equipment, primarily through (1) product sales of its imaging agent (e.g., per-dose/pe...

Read more

FluoGuide’s expected revenue model is based on commercializing its fluorescent imaging agent(s) for use alongside existing fluorescence-capable surgical imaging equipment, primarily through (1) product sales of its imaging agent (e.g., per-dose/pe...

FluoGuide A/S Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	385.00K	423.00K	6.51M	9.61M
Gross Profit	-571.17K	385.00K	423.00K	6.51M	9.61M
EBITDA	-40.42M	-32.81M	-43.90M	-32.21M	-28.65M
Net Income	-40.39M	-28.96M	-38.38M	-27.34M	-23.77M
Balance Sheet
Total Assets	88.34M	28.38M	29.61M	35.62M	53.31M
Cash, Cash Equivalents and Short-Term Investments	78.84M	18.61M	21.67M	26.01M	46.76M
Total Debt	28.30M	624.00K	10.83M	205.00K	57.00K
Total Liabilities	33.78M	5.31M	16.89M	3.65M	14.61M
Stockholders Equity	54.56M	23.07M	12.72M	31.97M	38.70M
Cash Flow
Free Cash Flow	-37.83M	-30.00M	-31.81M	-37.71M	-15.06M
Operating Cash Flow	-37.83M	-29.15M	-31.81M	-37.65M	-15.06M
Investing Cash Flow	-30.61M	-987.00K	-37.00K	-117.00K	0.00
Financing Cash Flow	99.33M	27.08M	27.50M	17.02M	51.18M

FluoGuide A/S Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 36.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Negative. The current price of 36 is below the 20-day moving average (MA) of 36.22, above the 50-day MA of 34.88, and below the 200-day MA of 38.51, indicating a neutral trend. The MACD of 0.77 indicates Positive momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 22.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:FLUO.

FluoGuide A/S Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NANEXA	56 Neutral	kr629.54M	-60.92	-48.65%	―	-60.33%	58.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLUO	47 Neutral	kr588.58M	-6.71	―	―	―	4.46%
ACE	44 Neutral	kr367.29M	-4.79	-79.60%	―	―	31.62%
IRLAB.A	43 Neutral	kr134.20M	-1.72	-199.86%	―	69.03%	23.10%
QLINEA	42 Neutral	kr435.72M	-0.91	-108.15%	―	270.64%	62.29%
GUARD	42 Neutral	kr26.30M	-0.24	-186.13%	―	―	0.30%